Advancements in cancer screening have continued to improve outcomes for the 44 per cent of Canadians who have, or will go on to develop cancer in their lifetime. Current tests, such as mammograms, Pap tests, colonoscopies and prostate-specific antigen (PSA) blood tests, have all contributed to early diagnoses, resulting in higher survival rates and reduced mortality. Now, there’s a new player in town: the Galleri test, created by GRAIL, a biotechnology company based in the United States. This test, which detects over 50 types of cancer, requires only a single blood draw. The test, which has undergone several clinical trials to get where it is today, is now officially available in Canada through Medcan , a health and wellness company specializing in preventive care. “It’s very unl

See Full Page